"Simvastatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.
| Descriptor ID |
D019821
|
| MeSH Number(s) |
D02.455.426.559.847.638.400.900 D04.615.638.400.900
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Simvastatin".
Below are MeSH descriptors whose meaning is more specific than "Simvastatin".
This graph shows the total number of publications written about "Simvastatin" by people in this website by year, and whether "Simvastatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 2000 | 2 | 0 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Simvastatin" by people in Profiles.
-
Cecen B, Keles D, Oktay G, Kozaci LD. Effects of simvastatin on matrix metalloproteinase regulation in IL-1?-induced SW1353 cells. Chem Biol Interact. 2019 Sep 01; 310:108730.
-
Shahrezaie M, Moshiri A, Shekarchi B, Oryan A, Maffulli N, Parvizi J. Effectiveness of tissue engineered three-dimensional bioactive graft on bone healing and regeneration: an in vivo study with significant clinical value. J Tissue Eng Regen Med. 2018 04; 12(4):936-960.
-
Teo KK, Goldstein LB, Chaitman BR, Grant S, Weintraub WS, Anderson DC, Sila CA, Cruz-Flores S, Padley RJ, Kostuk WJ, Boden WE. Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. Stroke. 2013 Oct; 44(10):2688-93.
-
Maron DJ, Hartigan PM, Neff DR, Weintraub WS, Boden WE. Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial). Am J Cardiol. 2013 Jun 01; 111(11):1557-62.
-
Ghavami S, Yeganeh B, Stelmack GL, Kashani HH, Sharma P, Cunnington R, Rattan S, Bathe K, Klonisch T, Dixon IM, Freed DH, Halayko AJ. Apoptosis, autophagy and ER stress in mevalonate cascade inhibition-induced cell death of human atrial fibroblasts. Cell Death Dis. 2012 Jun 21; 3:e330.
-
Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011 Dec 15; 365(24):2255-67.
-
Sicouri S, Gianetti B, Zygmunt AC, Cordeiro JM, Antzelevitch C. Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations. J Am Coll Cardiol. 2011 Feb 22; 57(8):986-93.
-
Culler SD, Weintraub WS. Is initiation of atorvastatin for employees a good buy for employers? Mayo Clin Proc. 2009 Dec; 84(12):1059-61.
-
Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol. 2008 Aug 19; 52(8):626-32.
-
Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, Weiss R, Cain VA, Raichlen JS. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J. 2006 May; 151(5):975.e1-9.